How to buy Beam Therapeutics stock | $90.71

Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics employs 266 staff and has a trailing 12-month revenue of around 0.00.

Beam Therapeutics stock price (NASDAQ: BEAM)

Use our graph to track the performance of BEAM stocks over time.

Beam Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$90.71
52-week range	$29.43 - $138.52
50-day moving average	$96.97
200-day moving average	$89.84
Wall St. target price	$128.57
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-7.12

Buy Beam Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Beam Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Beam Therapeutics price performance over time

Historical closes compared with the close of $90.71 from 2021-10-18

1 week (2021-10-12)	3.24%
1 month (2021-09-17)	-11.86%
3 months (2021-07-19)	0.48%
6 months (2021-04-19)	27.96%

1 year (2020-10-19)	184.54%
2 years (2019-10-15)	N/A
3 years (2018-10-15)	N/A
5 years (2016-10-15)	N/A

Beam Therapeutics financials

Revenue TTM	$24,000
Gross profit TTM	$-91,956,000
Return on assets TTM	-35.36%
Return on equity TTM	-104.63%
Profit margin	0%
Book value	$8.69
Market capitalisation	$6.2 billion

TTM: trailing 12 months

Shorting Beam Therapeutics shares

There are currently 5.0 million Beam Therapeutics shares held short by investors – that's known as Beam Therapeutics's "short interest". This figure is 3.5% down from 5.2 million last month.

There are a few different ways that this level of interest in shorting Beam Therapeutics shares can be evaluated.

Beam Therapeutics's "short interest ratio" (SIR)

Beam Therapeutics's "short interest ratio" (SIR) is the quantity of Beam Therapeutics shares currently shorted divided by the average quantity of Beam Therapeutics shares traded daily (recently around 743392.33038348). Beam Therapeutics's SIR currently stands at 6.78. In other words for every 100,000 Beam Therapeutics shares traded daily on the market, roughly 6780 shares are currently held short.

However Beam Therapeutics's short interest can also be evaluated against the total number of Beam Therapeutics shares, or, against the total number of tradable Beam Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Beam Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Beam Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1146% of the tradable shares (for every 100,000 tradable Beam Therapeutics shares, roughly 115 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Beam Therapeutics.

Find out more about how you can short Beam Therapeutics stock.

Beam Therapeutics share dividends

We're not expecting Beam Therapeutics to pay a dividend over the next 12 months.

Beam Therapeutics overview

Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc. ; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Beam Therapeutics is owned by insiders or institutions?
Currently 2.034% of Beam Therapeutics shares are held by insiders and 79.621% by institutions. How many people work for Beam Therapeutics?
Latest data suggests 266 work at Beam Therapeutics. When does the fiscal year end for Beam Therapeutics?
Beam Therapeutics's fiscal year ends in December. Where is Beam Therapeutics based?
Beam Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139 What is Beam Therapeutics's ISIN number?
Beam Therapeutics's international securities identification number is: US07373V1052 What is Beam Therapeutics's CUSIP number?
Beam Therapeutics's Committee on Uniform Securities Identification Procedures number is: 073730103